{"groups":[{"description":"Patients receive dexamethasone IV on days 1, 8, 15, and 22 of cycles 1-2 and IV on day 1 and PO on days 8, 15, and 22 of subsequent cycles and elotuzumab IV on days 1, 8, 15, and 22 of cycles 1-2 and day 1 of subsequent cycles. Patients also receive pomalidomide PO on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"FG000","title":"Treatment"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"37"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"37"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}